1. Paper › Research › Not peer-reviewed
2. Published

   Economic evaluation of steroid injections (methylprednisolone) in the treatment of Morton's neuroma: patient-blind randomised trial

   Hughes, D., Thomson, C., Beggs, I., Martin, D., McCaldin, D., Russell, D., Edwards, R. T., Hughes, D. A., Yeo, S. T., Russell, I. T. & Gibson, T. N., 1 Mar 2007.

   Research output: Contribution to conference › Paper

3. Published

   Effects of the abolition of prescription charges in Wales: A preliminary analysis

   Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Apr 2008.

   Research output: Contribution to conference › Paper

4. Published

   Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

   Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Mar 2006.

   Research output: Contribution to conference › Paper

5. Published

   Empirical analysis of the relationship between dose and duration of drug action

   Hughes, D. & Hughes, D. A., 1 Jun 2005.

   Research output: Contribution to conference › Paper

6. Published

   Engaging with the MRC Methodology Hubs – NWHTMR.

   Hughes, D. & Hughes, D. A., 1 Jan 2009.

   Research output: Contribution to conference › Paper

7. Published

   Enhancing methodical approaches for studying bilingualism in healthcare communication: report of a trial feasibility study.

   Roberts, G. W., Hughes, D., Roberts, G., Owen, H., Hughes, L., Whitaker, R., Deuchar, M., Hughes, D. A., Llewelyn, S., John, S., Irvine, F., Owen, B. & Rowlands, A., 1 Jan 2010.

   Research output: Contribution to conference › Paper

8. Published

   Factors influencing user choices to visit either general practitioners or community pharmacists for minor ailments – a discrete choice experiment

   Hughes, D., Hughes, D. A., Myles, S., Longo, M., Lisles, C. & Hood, K., 1 May 2007.

   Research output: Contribution to conference › Paper

9. Published

   Falls and hip-fractures: A cost-effectiveness analysis of risk assessment and interventions for community-dwelling older people

   Hughes, D., Gwynne, D., Hughes, D. A. & Edwards, R. T., 1 Mar 2007.

   Research output: Contribution to conference › Paper

10. Published

    Feasibility, validity and reliability of the Welsh EQ-5D health status questionnaire

    Hughes, D. & Hughes, D. A., 1 May 2007.

    Research output: Contribution to conference › Paper

11. Published

    Feasibility, validity and reliability of the Welsh EQ-5D health status questionnaire

    Hughes, D., 1 Mar 2007.

    Research output: Contribution to conference › Paper

12. Published

    From efficacy to cost-effectiveness: Impact of patient compliance

    Hughes, D. & Hughes, D. A., 1 Feb 2008.

    Research output: Contribution to conference › Paper

13. Published

    From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 May 2002.

    Research output: Contribution to conference › Paper

14. Published

    From efficacy to effectiveness and cost-effectiveness: modelling possibilities

    Hughes, D. & Hughes, D. A., 1 Nov 2004.

    Research output: Contribution to conference › Paper

15. Published

    Health and economic outcomes: Why compliance matters

    Hughes, D. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

16. Published

    Impact of non-compliance on the clinical and cost-effectiveness of statins

    Hughes, D. & Hughes, D. A., 1 Nov 2001.

    Research output: Contribution to conference › Paper

17. Published

    Impact of non-compliance on the cost-effectiveness of pharmaceuticals

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

18. Published

    Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.

    Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Jan 2009.

    Research output: Contribution to conference › Paper

19. Published

    Impact of the abolition of prescription charges in Wales: a multi-level modelling approach with application to time series dispensed rate data

    Hughes, D., Alam, F., Myles, S., Hughes, D. A., Dunstan, F., Routledge, P. & Cohen, D., 1 Sept 2007.

    Research output: Contribution to conference › Paper

20. Published

    Impact of the abolition of the prescription charge in Wales

    Hughes, D. & Hughes, D. A., 1 Nov 2008.

    Research output: Contribution to conference › Paper

21. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009.

    Research output: Contribution to conference › Paper

22. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009.

    Research output: Contribution to conference › Paper

23. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009, p. O41.

    Research output: Contribution to conference › Paper

24. Published

    Incorporating measures of compliance and persistence in pharmacoeconomic evaluations

    Hughes, D., Hughes, D. A. & Cowell, W., 1 Nov 2005.

    Research output: Contribution to conference › Paper

25. Published

    Integrating compliance and persistence in health economics models

    Hughes, D. & Hughes, D. A., 1 Jan 2008.

    Research output: Contribution to conference › Paper

26. Published

    Interventions that enhance medication compliance and persistence: Theoretical grounding, and economic assessment

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F., Elliott, R. & Cowell, W., 1 Oct 2007.

    Research output: Contribution to conference › Paper

27. Published

    Introduction to pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

28. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments

    Hughes, D. & Hughes, D. A., 1 May 2006.

    Research output: Contribution to conference › Paper

29. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Jun 2006.

    Research output: Contribution to conference › Paper

30. Published

    Methodological issues in the literature on costs of non-compliance in chronic diseases

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008.

    Research output: Contribution to conference › Paper

31. Published

    Modelling changes in first line antimalarial therapy

    Hughes, D. & Hughes, D. A., 1 Sept 2003.

    Research output: Contribution to conference › Paper

32. Published

    Orphan drug treatments: economic considerations

    Hughes, D. & Hughes, D. A., 1 Nov 2007.

    Research output: Contribution to conference › Paper

33. Published

    Patient compliance and persistence with prescribed medication: Measurement and health economic impact

    Hughes, D., Koncz, T., Hughes, D. A., Cleemput, I. & Annemans, L., 1 May 2004.

    Research output: Contribution to conference › Paper

34. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

35. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Oct 2001.

    Research output: Contribution to conference › Paper

36. Published

    Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

    Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Oct 2007.

    Research output: Contribution to conference › Paper

37. Published

    Pharmacoeconomic models that incorporate non-compliance

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

38. Published

    Pharmacoeconomics appraisals by the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

39. Published

    Pharmacoeconomics in Wales: functions of the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Apr 2004.

    Research output: Contribution to conference › Paper

40. Published

    Pharmacoeconomics of pharmacogenetic testing: azathioprine

    Hughes, D., McAllister, R. & Hughes, D. A., 1 Apr 2004.

    Research output: Contribution to conference › Paper

41. Published

    Pharmacokinetics, patient compliance and pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Jun 2005.

    Research output: Contribution to conference › Paper

42. Published

    Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

    Hughes, D., Hughes, D. A. & Walley, T., 1 Sept 2001.

    Research output: Contribution to conference › Paper

43. Published

    Physchiatrist prescribing preferences and attitudes toward promotion

    Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

44. Published

    Population pharmacokinetics of warfarin: Intermin analysis of the Liverpool pharmacogenetic prospective cohort study

    Hughes, D., Matthews, I., Aarons, L., Al-Zubiedi, S., Hatch, E., Lane, S., Williamson, P., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Nov 2007.

    Research output: Contribution to conference › Paper

45. Published

    Pragmatic trials - design features and implications for clinical decision making

    Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Aug 2000.

    Research output: Contribution to conference › Paper

46. Published

    Prescription fee exemption research study

    Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Jun 2006.

    Research output: Contribution to conference › Paper

47. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Jul 2005.

    Research output: Contribution to conference › Paper

48. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Jan 2006.

    Research output: Contribution to conference › Paper

49. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Nov 2005.

    Research output: Contribution to conference › Paper

50. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Nov 2005.

    Research output: Contribution to conference › Paper

51. Published

    Public meetings of the NICE appraisals committee

    Hughes, D. & Hughes, D. A., 1 Dec 2007.

    Research output: Contribution to conference › Paper

52. Published

    Quantitative risk-benefit analysis

    Hughes, D. & Hughes, D. A., 1 May 2007.

    Research output: Contribution to conference › Paper

53. Published

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

54. Published

    Systematic review of follow-up of cancer in primary care verses secondary care: findings for breast and lung cancer

    Hughes, D., Lewis, R., Neal, R. D., France, B., Williams, N. H., Wilkinson, C., Russell, I. T., Russell, D., Hughes, D. A., Stuart, N. S. & Weller, D., 1 Mar 2007.

    Research output: Contribution to conference › Paper

55. Published

    The all wales medicines strategy group: assessments and appraisals

    Hughes, D. & Hughes, D. A., 1 Nov 2008.

    Research output: Contribution to conference › Paper

56. Published

    The assessment, determinants & economics of medication compliance & persistence

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Oct 2007.

    Research output: Contribution to conference › Paper

57. Published

    The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

    Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Mar 2008.

    Research output: Contribution to conference › Paper

58. Published

    The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 May 2008.

    Research output: Contribution to conference › Paper

59. Published

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

60. Published

    The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

    Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Nov 2007.

    Research output: Contribution to conference › Paper

61. Published

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Nov 2000.

    Research output: Contribution to conference › Paper

62. Published

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Dec 2007.

    Research output: Contribution to conference › Paper

63. Published

    The population pharmacokinetics of lapdap

    Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

64. Published

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Nov 2006.

    Research output: Contribution to conference › Paper

65. Published

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

66. Published

    What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

    Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 May 2007.

    Research output: Contribution to conference › Paper

67. Paper › Research › Peer-reviewed
68. Published

    A Systematic Review of Patient Preferences for Subcutaneous Medications

    Ridyard, C., Dawoud, D. & Hughes, D., Nov 2013.

    Research output: Contribution to conference › Paper › peer-review

69. Published

    Identification Of Items For A Standardised Resource-Use Measure: Review Of Current Instruments

    Thorn, J. C., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S. & Hollingworth, W., Nov 2015.

    Research output: Contribution to conference › Paper › peer-review

70. Published

    Review of the Use of Resource Use Instruments Based on Patient Recall in Relation to Other Methods of Cost Estimation

    Ridyard, C. & Hughes, D., Nov 2013.

    Research output: Contribution to conference › Paper › peer-review

71. Published

    Review of the use of resource use instruments based on patient recall in relation to other methods of resource use estimation

    Ridyard, C. & Hughes, D., Nov 2013.

    Research output: Contribution to conference › Paper › peer-review

72. Published

    Screening log data can be used to inform protocol modifications, increasing patient recrutiment to a challanging clinical trial

    Blair, J., Awoyale, L., Thornborough, K., Peak, M., Didi, M., Bedson, E., Hughes, D., Ridyard, C., Tat, T. & Gregory, J., Nov 2013.

    Research output: Contribution to conference › Paper › peer-review

73. Poster › Research › Peer-reviewed
74. Published

    Carer-administration of as-needed sub-cutaneous medication for breakthrough symptoms in homebased dying patients: a UK study (CARIAD)

    Wilkinson, C., Poolman, M., Roberts, J., Wee, B., Hiscock, J., Hughes, D., Nelson, A., Perkins, P., Johnstone, R. P., Reymond, E., Foster, B., O'Connor, J., Jones, S., Hoare, Z., Roberts, R., Byrne, A., Healy, S. & Lewis, P., 1 Sept 2017.

    Research output: Contribution to conference › Poster › peer-review

75. Published

    Comparison of regression methods for the cost effectiveness analysis of clinical trials with a small population size: the sycamore and folated trials

    Culeddu, G., Hughes, D. & Welton, N., 10 Jul 2017.

    Research output: Contribution to conference › Poster › peer-review

76. Published

    Core items for a standardised resource-use measure (ISRUM):expert Delphi consensus survey

    Thorn, J., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S., Thornton, G. & Hollingworth, W., 7 May 2017, p. P265. 1 p.

    Research output: Contribution to conference › Poster › peer-review

77. Published

    Health Economics Analysis Plans: Where Are We Now?

    Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 3 Nov 2016, p. A397. 1 p.

    Research output: Contribution to conference › Poster › peer-review

78. Published

    Health economics analysis plans: the current state of play

    Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 7 May 2017, p. P144. 1 p.

    Research output: Contribution to conference › Poster › peer-review

79. Published

    Patient-level information and costing systems (PLICS) as a source of routinely collected cost data for trial-based economic evaluations

    Ridyard, C. & Hughes, D., 7 May 2017, p. P141. 1 p.

    Research output: Contribution to conference › Poster › peer-review

80. Abstract › Research › Peer-reviewed
81. Published

    Continuous subcutaneous insulin infusion compated to multiple daily injection regimens in children and yung people at diagnosis of type 1 diabetes: A pragmatic randomised controlled trial and economic evaluation (scipi trial)

    Blair, J., Mckay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., John, G., Hughes, D. & Gamble, C., Sept 2017, p. 22-23.

    Research output: Contribution to conference › Abstract › peer-review

82. Other › Research › Peer-reviewed
83. Published

    Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa

    Culeddu, G., Brogan, P. A. & Hughes, D., 2021.

    Research output: Contribution to conference › Other › peer-review

84. Commissioned report › Research › Not peer-reviewed
85. Published

    A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

    Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/Report › Commissioned report

86. Published

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

87. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

88. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

89. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

90. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

91. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

92. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

93. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

94. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

95. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

96. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

97. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

98. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

99. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

100. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

101. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

102. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

     Research output: Book/Report › Commissioned report

103. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

104. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

105. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

106. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report